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A B S T R A C T
The involvement of angiogenesis in disease and its potential as a therapeutic target have been firmly established
over recent decades. Endothelial cells (ECs) are central elements in vessel homeostasis and regulate the passage
of material and cells into and out of the bloodstream. EC proliferation and migration are modified by alterations
to mitochondrial biogenesis and dynamics resulting from several signals and environmental cues, such as
oxygen, hemodynamics, and nutrients. As intermediary signals, mitochondrial ROS are released as important
downstream modulators of the expression of angiogenesis-related genes. In this review, we discuss the
physiological actions of these signals and aberrant responses during vascular disorders.
1. Mitochondria in endothelial cells
The entire vascular system, from the heart to the smallest capillary,
is lined by endothelial cells (EC). ECs are central elements in vessel
homeostasis and regulate and passage of materials and cells into and
out of the bloodstream. Every metabolically active tissue requires the
development of an angiogenic network, and the development of this
network is associated with metabolic changes and accompanying
morphological and phenotypical variations in ECs. In most cell types,
the key metabolic regulators are mitochondria, which are linked to a
diversity of regulatory processes that allow cell proliferation [1] or
trigger apoptosis [2], and also signals to nucleolus [3]. Mitochondrial
content varies between endothelial beds; for example, brain ECs contain
more mitochondria than ECs in other tissues. However, mitochondrial
content in all ECs is low (2–6% of cytoplasm volume) compared with
other cell types for example cardiomyocytes (about 32%) [4,5]. ECs
have an absolute requirement for glucose and generate more than 80%
of their ATP through glycolysis, and the low mitochondrial content in
ECs is thus consistent with a role in regulating signaling responses to
environmental cues rather than in energy production. Indeed, the
activity of EC mitochondria is influenced by a variety of circulating
factors, and these organelles provide important factors for ECs signaling
(Fig. 1) [6–8].
1.1. Mitochondrial features: distribution, biogenesis and dynamics
The communication of EC mitochondria with other organelles is
determined by their distribution, biogenesis, and dynamics [9]. For
example, mitochondria are anchored to the cytoskeleton in coronary
arterioles isolated from human myocardium; reactive oxygen species
(ROS) released from these mitochondria in response to shear stress
contribute to flow-mediated dilatation [10]. In pulmonary artery ECs,
hypoxia triggers a perinuclear mitochondrial redistribution, with con-
comitant ROS accumulation in the nucleolus and induction of hypoxia-
induced genes [3].
An increase in mitochondrial mass requires the coordinated replica-
tion and expression of mitochondrial DNA (mtDNA) with the parallel
expression of nuclear-encoded mitochondrial genes. A key player in this
coordination is proliferator-activated receptor-γ coactivator-1α (PGC-
1α), which activates nuclear respiratory factors 1 and 2 and the nuclear
expression of genes necessary for mitochondrial biogenesis [11]. In
parallel, PGC-1α also activates mitochondrial transcription factors A
and B (TFAM and TFBM), which regulate the expression of mtDNA
genes. PGC-1α is expressed in ECs and regulates mitochondrial biogen-
esis and the expression of several mitochondrial antioxidant enzymes,
playing a dual role in the protection against oxidative stress by
supplying undamaged mitochondria and enhancing ROS defenses
[12,13]. PGC-1α expression and mitochondrial biogenesis are affected
by several factors, such as hypoxia and caloric restriction, in parallel
with variations in vessel formation [14–16]. PGC-1α moreover reg-
ulates the expression of several genes related to lipid and glucose
metabolism [14,15], induces VEGF expression [17], and decreases
apoptosis [18], resulting in a coordinated acceleration of angiogenesis
as ECs increase their metabolic demands during proliferation.
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Mitochondria are highly dynamic organelles that undergo cycles of
fusion and fission that maintain mitochondrial integrity and intersect
with apoptosis pathways [19]. Key regulators of this process include
mitofusin-1 and 2 (MFN-1 and 2) and optic atrophy protein 1 (OPA-1).
These proteins regulate fission-1 (FIS-1), which recruit DRP-1 (dyna-
min-related protein-1) to initiate the fission process. Fusion and fission
are physiologically balanced processes. Fusion allows a better distribu-
tion of proteins, mtDNA, and metabolites to maintain electrical and
biochemical connectivity [11]. Fusion is a determining factor in
angiogenesis that can accelerate responses to VEGF and the activation
of eNOS [20]. Fission, on the other hand, is a key factor in vascular
sprouting. In pulmonary ECs, DRP-1 activation, which induces mito-
chondrial fission, stimulates angiogenesis by promoting proliferation,
migration, and inhibition of apoptosis in a mitochondrial Ca2+-
dependent manner [19,21]. A defective mitochondrial network is
observed in several pathological settings, such as high glucose and
ischemia-reperfusion, and also during EC aging, highlighting the
importance of the fusion/fission cycle during disease development
[22–25]. Accumulated mitochondrial damage leads to a rearrangement
of these networks, and organelles with normal membrane potential and
functional components are reincorporated into mitochondrial networks
after fission. In contrast, dysfunctional mitochondria cannot fuse with
the network and become targets for elimination by mitophagy, the
destruction of damaged mitochondria by autophagy degradation.
Mitophagy enables ECs to purge defective organelles and thus avoid
dysfunctional signaling to prevents apoptosis. In parallel with mito-
phagy, biogenetic mechanisms act during homeostasis to replace the
loss of mitochondrial mass, providing a mechanism to control mito-
chondria quality [11,26,27]. Mitophagy during homeostasis is crucially
regulated by mitochondrial membrane depolarization. The PTEN-
induced putative kinase 1(PINK1) is normally recruited and degraded
at the inner mitochondrial membrane. When mitochondria are da-
maged, membrane potential loss prevents PINK1 degradation, and its
accumulation induce mitophagy. This process is led by the E3 ubiquitin
ligase Parkin, that ubiquitinate mitochondrial proteins, promoting the
organelle recognition and recruitment by the autophagosome [28–30].
Stimuli such as metabolic stress trigger mitophagy to protect EC
mitochondria from damage [31]. Deregulation of mitophagy results
in ROS production, inflammation, and cell death, ultimately leading to
neurodegeneration [30], cardiovascular disease [32], and endothelial
dysfunction during aging [33]. Mitophagy is activated in ECs by
mitochondrial depolarization triggered by exposure to hydrogen per-
oxide, irradiation, or promoters of lipid peroxidation [27,34,35].
Recent reports demonstrate that PINK and Parkin are unregulated in
diabetic and obese mice, and knock down of these proteins in the
vascular wall resulted in deregulation of mitophagy, with a concomi-
tant accumulation of damaged mitochondria and ROS, resulting in
apoptosis. Administration of low doses of palmitic acid stimulates PINK-
Parkin pathway to eliminate damaged EC mitochondria; however,
under severe stress this mechanism of protection is shut down and
the accumulated defective mitochondria trigger cell death [36]. Thus,
the PINK-Parkin pathway, by promoting mitophagy, protects ECs from
metabolic stress and has potential as a target for the prevention of
cardiovascular disorders triggered by oxidative stress in the endothe-
lium [11,36,37].
2. Mitochondria in endothelial cells: responses to environmental
cues
2.1. The role of oxygen in EC mitochondrial behavior
Oxygen carried in from circulating blood transfers to perivascular
Fig. 1. A blood vessel delimited by ECs and some of the signals which affect angiogenic behavior via mitochondria. The cells at the top represent the effect on mitochondria of nutrients,
oxygen, and shear stress (LSS, laminar shear stress; PSS, pulsatile shear stress; OSS, oscillatory shear stress) and how some of the signals released affect the expression of angiogenic genes.
The cells at the bottom represent mitochondrial biogenesis, distribution, and dynamics and the consequences of these processes on EC proliferation and vessel sprouting.
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tissues through ECs. Oxygen consumption by ECs is relatively low
compared with other cell types, contributing to just 15% of EC ATP
generation [7]. This low consumption allows ECs to transfer most of the
oxygen to perivascular tissues [38]. A sharp drop in oxygen levels
across the arteriolar vessel wall is proposed to reflect fast diffusion
through the endothelium [39,40]; however, these observations are still
debated due to discrepant reports. The vessel wall has been proposed to
act as an “oxygen sink”, preventing potential harmful effects due to
oxidative stress in perivascular tissues [41]. Despite their normally low
oxygen utilization, EC mitochondria are able to increase respiration
substantially in response stress stimuli such as glucose deprivation or
oxidative stress [43,43].
ECs are quite sensitive to hypoxic environments, and their mito-
chondria participate in the response to hypoxia by initiating the
angiogenic cascade. A hypoxic environment increases VEGF levels,
which enhance mitochondrial biogenesis via AKT-dependent signaling,
resulting in increased vascular branching [44]. Conversely, vessel
branching is reduced upon inhibition of EC mitochondrial biogenesis
by silencing sirtuin 1 (SIRT1) [45]. The response of ECs to oxygen
involves the inner mitochondrial membrane protein UCP-2 (uncoupling
protein 2). In a model of pulmonary hypertension induced by inter-
mittent hypoxia, UCP-2 promotes mitophagy and inadequate mitochon-
drial biogenesis and increases apoptosis in the lung endothelium [46].
During development, the vascular system shifts to a more oxygenated
environment by increasing postnatal mitochondrial biogenesis through
a decrease in HIF expression [47].
2.2. The role of dietary nutrients in EC behavior via mitochondria
ECs follow a very strict metabolic program in accordance to the
required phenotype. For example, in a non-growing tissue, quiescent EC
show a simultaneous reduction of mitochondrial respiration and
glycolysis [48] whereas in sprouted vessels, tip ECs rely more in
anaerobic glycolysis than in mitochondria (glucose can diffuse faster
than oxygen allowing migration of EC to the new vessel). However stalk
ECs use fatty acid oxidation and its ablation impairs proliferation
[49,50]. On the other hand, EC mitochondria are sensitive to variations
in nutrient availability, which has an impact on its metabolic repro-
graming and further vascular properties. One of the best-studied
nutritional effects on EC mitochondria is the impact of chronic elevated
glucose, as occurs in diabetes. Elevated blood glucose causes EC injury
and increased apoptosis, resulting in impaired endothelial integrity and
blood vessel function [51]. Glucose-induced endothelial injury alters
mitochondrial dynamics, with an increase in organelle fission leading to
mitochondrial fragmentation, elevated ROS production, and EC dys-
function and apoptosis [52]. High glucose also modifies mitochondrial
morphology and ultrastructure (increasing vacuolation and disrupting
cristae) via activation of metalloproteinase 9, resulting in altered
mitochondrial membrane potential [53]. High glucose also down-
regulates mitochondrial biogenesis via a significant decrease in PGC-
1α expression [54]. PGC-1α downregulation by high glucose is
paralleled in HUVECs by increased expression of VDAC1 (voltage-
dependent anion channel 1), which may underlie glucose-induced EC
apoptosis [55]. In contrast, in vivo models of diabetes type 2 and
human samples reveal that, PGC-1α expression increase in parallel to a
defective angiogenesis, while PGC-1α loss of function improves vascu-
lature [56]. However in other models of vascular damage and hyper-
tension PGC-1α up-regulation exert a protective role in angiogenesis,
reflecting a contribution of PGC-1α to endothelial phenotype in a
context-dependent manner [57].
EC function is also modulated by lipids. Fatty acid oxidation,
especially when cells are supplied with L-carnitine, may be critical
for mitochondrial angiogenic signaling [58–61]. In a model of con-
genital heart disease, L-carnitine supplementation of cultured lung ECs
reduces oxidative stress, NO signaling, and mitochondrial function.
Little is known about the direct participation of lipids other than fatty
acids in angiogenic mitochondrial signaling; however, there is evidence
for indirect action. For example, efficient cholesterol efflux from ECs
affects VEGF-induced angiogenesis, influencing oxidative stress and,
indirectly, mitochondrial biogenesis [44,62].
Clinical studies show a close relation between dietary protein intake
and endothelial function or dysfunction [63]. Several amino acids
metabolized by ECs have the potential to modulate angiogenesis
[64–68]. Glutamine not only serves as a fuel source in ECs; it also
affects vessel branching and EC proliferation via unknown mechanisms
[69,70]. Arginine affects EC ROS production and thus angiogenesis
[71,72].
2.3. The role of hemodynamics
The vascular endothelium is constantly exposed to blood fluid
hemodynamic forces (mainly shear stress), and this is both a key
determinant of EC function and a critical step toward the development
of coronary atherosclerosis [73,74]. EC dysfunction is the first event in
atherosclerosis, triggering a series of changes that lead to the develop-
ment of cardiovascular diseases. Local hemodynamic forces contribute
to defective EC function through mitochondrial oxidative stress. Blood
flow occurs in three forms: steady, when the fluid velocity does not
change (laminar shear stress; LSS); pulsatile, when there is unidirec-
tional flow with a periodic variation in magnitude (pulsatile shear
stress; PSS); and oscillatory, when flow is bidirectional with a periodi-
cally varying magnitude (oscillatory shear stress; OSS). LSS, PSS, and
OSS modulate EC function in different ways; for example, exposure to
LSS or PSS, but not OSS, induces vasodilation by activating eNOS-
mediated NO production [75–78]. LSS and PSS also upregulate mRNA
expression of the mitochondrial ROS scavenger MnSOD, thereby
preventing oxidative-stress-induced damage [79]. In contrast, OSS
increases NADPH oxidase expression, thereby increasing free radical
production [80]. Overall, OSS upregulates proatherogenic genes and
suppresses atheroprotective genes, promoting disease initiation,
whereas LSS and PSS have the opposite effect [81]. Moreover, LSS
can inhibit electron transport chain (ETC), reducing ROS production in
proportion to the degree of flow exposure [82]. The effects of LSS and
PSS on EC mitochondria and ROS production can be summarized as
follows. Shear stress onset transiently increases intercellular calcium,
which can induce ROS formation by enhancing tricarboxylic acid cycle
activity and enhancing electron flow to the ETC. The resulting activa-
tion of eNOS increases NO production, inducing ROS formation but also
activating mitochondrial ROS scavenging. Mitochondrial membrane
polarization is maintained during LSS but is hyperpolarized during PSS,
explaining the elevated mitochondrial ROS production in this situation.
Despite these ROS increases, mitochondria remain healthy due to NO-
mediated caspase inhibition, maintenance of membrane polarity,
mitochondrial biogenesis, and upregulation of antioxidant genes [81].
Shear stress also influences mitochondrial dynamics. For example,
LSS activates signaling pathways that modulate mitochondrial fission
by recruiting cytosolic Drp1. These signals lead to changes in respira-
tion rate that increase mitochondrial membrane potential and ROS
generation, triggering subsequent activation of PRX3 an antioxidant
enzyme [83]. Moreover, in a cellular model of ischemia/reperfusion,
ECs increase production of mitochondrial ROS and NO, and during
reperfusion Drp1 activation is accompanied by increased mitochondrial
fission; these events are not induced by LSS alone, suggesting that LSS
and PSS together modulate oxidative stress in ECs during reperfusion,
regulating mitochondrial fission and promoting apoptosis [81]. In line
with these findings, exposure to LSS and PSS activates AMPK and JNK,
altering cell redox status and modifying autophagosome formation in
ECs. Interestingly, LSS has been shown to activate autophagy in
cultured ECs or isolated rabbit carotid arteries [84–86].
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3. Mitochondrial ROS: one signal, diverse endothelial actions
The past 10 years have seen a growing interest in the role of
mitochondrial ROS in ECs. Mitochondrial ROS come from several
sources, and have important signaling functions in ECs directly linked
to health and disease processes. The principal ROS producers are
complexes I and III in the OXPHOS system; however, their specific
contribution to total mitochondrial ROS production in ECs remains
unclear due to the existence of other sources of ROS [87]. One of the
main enzymes linked to mitochondrial ROS production is the ECs
highly expressed nicotinamide adenine dinucleotide phosphate oxidase
4 (NOX4) [88]. NOX4-mediated regulation of mitochondrial ROS
signaling influences endothelial-dependent relaxation and therefore
blood pressure [89]. In addition, NOX activity in ECs is increased by
cholesterol, particularly LDL, resulting in altered ROS levels and
promoting cell senescence [90]. In addition, NOX can affect ROS
production and signaling during cell migration, angiogenesis, adaptive
responses to hypoxia, oxidative stress [91], and stroke [92].
Another potential source of mitochondrial ROS is the growth factor
adaptor protein p66Shc. Although its precise function remains unde-
fined, the oxidation of cytochrome c by p66Shc generates hydrogen
peroxide. In the presence of specific signals, for example high glucose or
apoptosis inducers, p66Shc translocate to the mitochondrial intermem-
brane space, where they initiate ROS-mediated signals that might
trigger endothelial dysfunction or apoptosis [93–98]. p66Shc thus
appears to transduce environmental signals into mitochondrial ROS
that trigger downstream responses in ECs, with strong implications for
vascular biology.
Other contributors to mitochondrial ROS production include the
monoamine oxidases (MAO), an enzyme family mainly localized to the
outer mitochondrial membrane. Although ECs express MAO, its rele-
vance to EC function is poorly understood [99]. However, MAO-derived
ROS are associated with cardiac failure and adverse remodeling in mice
as a response to pressure overload [100,101]. Other implicated signals
include those already discussed, such as oxygen, nutrients, and
hemodynamics and also ROS themselves, derived either from mito-
chondria or from other sources. Non-mitochondrial ROS can initiate
mitochondrial ROS production through a process called ROS-induced
ROS release [102]. After exposure to angiotensin II, ROS induced by
NOX for example, stimulate ROS production at mitochondria through
mitoKATP channel opening, mitochondrial membrane depolarization
and permeability transition pore, protecting ECs from excessive NO
production [103,104]. It is proposed that ROS signals are amplified
under physiological conditions by ROS-induced ROS release mechanism
contributing to EC dysfunction and disease progression [102].
3.1. Mitochondrial ROS in EC physiology and pathophysiology
ROS have traditionally been considered toxic metabolites that
adversely affect vascular function through direct damage to several
EC processes. However, more recent research identifies the participa-
tion of ROS as signaling molecules in EC regulatory cascades [17]. In
this view, mitochondrial ROS are tightly regulated signals in ECs with
an important role in physiological and pathophysiological settings.
Mitochondrial ROS have well-documented effects on several EC pro-
cesses related to normal vascular biology, such as shear-stress-induced
vasodilation, hypoxia signaling, autophagy, and proinflammatory acti-
vation. Another example of ROS signaling is flow-mediated dilatation of
arterioles from human myocardium [10]. Moreover, the use of mito-
chondrial ROS scavengers provides indirect evidence of the physiolo-
gical actions of mitochondrial ROS; for example, oral antioxidant drugs
blunt flow-mediated dilatation of the brachial artery, and the lack of
benefit of high doses of nonselective antioxidants in cardiovascular
diseases hints at the participation of mitochondrial ROS in normal EC
function [105,106].
Several pathological factors affect ROS production by ECs, and
excessive mitochondrial ROS accumulation in ECs has been linked to
the development of vascular diseases. For example, mitochondrial ROS
are important intermediaries in the oxidation of lipids implicated in
LDL-mediated initiation of cardiovascular disease associated with
dyslipidemia; however, oxidized lipid production can also increase
antioxidant gene expression, thus triggering a mechanism for attenuat-
ing excessive oxidative stress [106–109]. Another example is hyperten-
sion, which is linked to elevated mitochondrial superoxide in vascular
cells, and can be reduced with superoxide scavengers in animal models
[110–114]. Further evidence for a link between mitochondrial ROS and
hypertension is provided by the NOX family of ROS-producing en-
zymes, which together with mitochondria generate excessive ROS in
angiotensin-II-related models [115–117]. In contrast, ROS production
and angiotensin-II-induced hypertension are suppressed in transgenic
mice overexpressing mitochondrial matrix-based thioredoxin-2 [117].
Age-related hypertensive responses in rats are also attenuated by
supplementation with the mitochondrial antioxidant MitoQ [118].
Two well-documented examples of the role of mitochondrial ROS in
vascular signaling are linked to diabetes and atherosclerosis. In
diabetes, elevated circulating glucose and free fatty acids induce EC
mitochondrial fission, with concomitantly high levels of ROS that lead
to blunted cell growth and altered cell-adhesion molecule expression on
the cell surface [119–121]. Excessive mitochondrial ROS production in
diabetes has been described as a master switch for the activation of
subsequent events linked to endothelial dysfunction, such as activation
of protein kinase C, increased polyol and hexosamine pathway flux, and
increased age-related glycation end-product formation [122]. The
influence of excessive ROS production on atherosclerosis is supported
by multiple lines of evidence, including oxidative damage to mtDNA by
ROS-induced ROS that is directly linked to the degree of arterial
damage [17,123]. Moreover, mitochondrial membrane hyperpolariza-
tion triggers further ROS generation and accelerates atherosclerosis
progression [17].
4. Conclusions
ECs regulate the passage of materials and cells between the blood
stream and tissues. Within this process, EC mitochondria integrate
environmental cues such as oxygen, hemodynamics, and nutrients by
modifying their biogenesis, dynamics, and programmed degradation.
These processes determine the EC phenotype in physiological or
pathological conditions. EC mitochondria additionally release ROS as
signals with important downstream actions that include the expression
of angiogenesis-related genes in physiological conditions and also in
aberrant responses during vascular disease.
Acknowledgments
We thank M. M. Muñoz-Hernandez and Dr Concepción Jimenez for
technical assistance, Keren López Fernández for the artwork in Fig. 1
and Simon Bartlett for English editing. This study was supported by
MINECO: SAF2015-65633-R MSCA-COFUND-DP Doctoral programmes
2014. The CNIC is supported by MINECO and Pro-CNIC Foundation,
and is a SO-MINECO (award SEV-2015-0505).
References
[1] D. Mitra, D.E. Fisher, Transcriptional regulation in melanoma, Hematol. Oncol.
Clin. North Am. 23 (2009) 447–465.
[2] G. Kroemer, L. Galluzzi, C. Brenner, Mitochondrial membrane permeabilization in
cell death, Physiol. Rev. 87 (2007) 99–163.
[3] A.B. Al-Mehdi, V.M. Pastukh, B.M. Swiger, D.J. Reed, M.R. Patel, G.C. Bardwell,
V.V. Pastukh, M.F. Alexeyev, M.N. Gillespie, Perinuclear mitochondrial clustering
creates an oxidant-rich nuclear domain required for hypoxia-induced transcrip-
tion, Sci. Signal. (5 () (2012) (ra47).
[4] E. Barth, G. Stammler, B. Speiser, J. Schaper, Ultrastructural quantitation of
mitochondria and myofilaments in cardiac muscle from 10 different animal
species including man, J. Mol. Cell. Cardiol. 24 (1992) 669–681.
S. Caja, J.A. Enríquez Redox Biology 12 (2017) 821–827
824
[5] W.H. Oldendorf, M.E. Cornford, W.J. Brown, The large apparent work capability
of the blood-brain barrier: a study of the mitochondrial content of capillary
endothelial cells in brain and other tissues of the rat, Ann. Neurol. 1 (1977)
409–417.
[6] O. Culic, M.L. Gruwel, J. Schrader, Energy turnover of vascular endothelial cells,
Am. J. Physiol. 273 (1997) C205–C213.
[7] K. De Bock, M. Georgiadou, P. Carmeliet, Role of endothelial cell metabolism in
vessel sprouting, Cell Metab. 18 (2013) 634–647.
[8] A. Krutzfeldt, R. Spahr, S. Mertens, B. Siegmund, H.M. Piper, Metabolism of
exogenous substrates by coronary endothelial cells in culture, J. Mol. Cell. Cardiol.
22 (1990) 1393–1404.
[9] J. Park, J. Lee, C. Choi, Mitochondrial network determines intracellular ROS
dynamics and sensitivity to oxidative stress through switching inter-mitochondrial
messengers, PLoS One 6 (2011) e23211.
[10] Y. Liu, H. Li, A.H. Bubolz, D.X. Zhang, D.D. Gutterman, Endothelial cytoskeletal
elements are critical for flow-mediated dilation in human coronary arterioles,
Med. Biol. Eng. Comput. 46 (2008) 469–478.
[11] M.A. Kluge, J.L. Fetterman, J.A. Vita, Mitochondria and endothelial function, Circ.
Res. 112 (2013) 1171–1188.
[12] I. Valle, A. Alvarez-Barrientos, E. Arza, S. Lamas, M. Monsalve, PGC-1alpha
regulates the mitochondrial antioxidant defense system in vascular endothelial
cells, Cardiovasc. Res. 66 (2005) 562–573.
[13] A.J. Afolayan, A. Eis, M. Alexander, T. Michalkiewicz, R.J. Teng,
S. Lakshminrusimha, G.G. Konduri, Decreased endothelial NOS expression and
function contributes to Impaired mitochondrial biogenesis and oxidative stress in
fetal lambs with PPHN, Am. J. Physiol. Lung Cell. Mol. Physiol. (2015)
(ajplung00392 02014).
[14] T.C. Leone, D.P. Kelly, Transcriptional control of cardiac fuel metabolism and
mitochondrial function, Cold Spring Harb. Symp. Quant. Biol. 76 (2011) 175–182.
[15] I.S. Patten, Z. Arany, PGC-1 coactivators in the cardiovascular system, Trends
Endocrinol. Metab. 23 (2012) 90–97.
[16] J.S. Kim, B. Kim, H. Lee, S. Thakkar, D.M. Babbitt, S. Eguchi, M.D. Brown,
J.Y. Park, Shear stress-induced mitochondrial biogenesis decreases the release of
microparticles from endothelial cells, Am. J. Physiol. Heart Circ. Physiol. 309
(2015) H425–H433.
[17] M.E. Widlansky, D.D. Gutterman, Regulation of endothelial function by mito-
chondrial reactive oxygen species, Antioxid. Redox Signal. 15 (2011) 1517–1530.
[18] J. Li, Y. Zhang, Y. Liu, T. Shen, H. Zhang, Y. Xing, D. Zhu, PGC-1alpha plays a
major role in the anti-apoptotic effect of 15-HETE in pulmonary artery endothelial
cells, Respir. Physiol. Neurobiol. 205 (2015) 84–91.
[19] D.F. Suen, K.L. Norris, R.J. Youle, Mitochondrial dynamics and apoptosis, Genes
Dev. 22 (2008) 1577–1590.
[20] J.J. Lugus, G.A. Ngoh, M.M. Bachschmid, K. Walsh, Mitofusins are required for
angiogenic function and modulate different signaling pathways in cultured
endothelial cells, J. Mol. Cell. Cardiol. 51 (2011) 885–893.
[21] T. Shen, N. Wang, X. Yu, J. Shi, Q. Li, C. Zhang, L. Fu, S. Wang, Y. Xing, X. Zheng,
L. Yu, D. Zhu, The Critical Role of Dynamin-Related Protein 1 in Hypoxia-Induced
Pulmonary Vascular Angiogenesis, J. Cell. Biochem. 116 (2015) 1993–2007.
[22] R.J. Giedt, C. Yang, J.L. Zweier, A. Matzavinos, B.R. Alevriadou, Mitochondrial
fission in endothelial cells after simulated ischemia/reperfusion: role of nitric
oxide and reactive oxygen species, Free Radic. Biol. Med. 52 (2012) 348–356.
[23] J.R. Lin, W.L. Shen, C. Yan, P.J. Gao, Downregulation of dynamin-related protein 1
contributes to impaired autophagic flux and angiogenic function in senescent
endothelial cells, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 1413–1422.
[24] J. Paltauf-Doburzynska, R. Malli, W.F. Graier, Hyperglycemic conditions affect
shape and Ca2+ homeostasis of mitochondria in endothelial cells, J. Cardiovasc.
Pharmacol. 44 (2004) 423–436.
[25] S.M. Shenouda, M.E. Widlansky, K. Chen, G. Xu, M. Holbrook, C.E. Tabit,
N.M. Hamburg, A.A. Frame, T.L. Caiano, M.A. Kluge, M.A. Duess, A. Levit, B. Kim,
M.L. Hartman, L. Joseph, O.S. Shirihai, J.A. Vita, Altered mitochondrial dynamics
contributes to endothelial dysfunction in diabetes mellitus, Circulation 124 (2011)
444–453.
[26] D.R. Green, L. Galluzzi, G. Kroemer, Mitochondria and the autophagy-inflamma-
tion-cell death axis in organismal aging, Science 333 (2011) 1109–1112.
[27] S. Mai, B. Muster, J. Bereiter-Hahn, M. Jendrach, Autophagy proteins LC3B, ATG5
and ATG12 participate in quality control after mitochondrial damage and
influence lifespan, Autophagy 8 (2012) 47–62.
[28] S. Geisler, K.M. Holmstrom, D. Skujat, F.C. Fiesel, O.C. Rothfuss, P.J. Kahle,
W. Springer, PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/
SQSTM1, Nat. Cell Biol. 12 (2010) 119–131.
[29] C. Vives-Bauza, C. Zhou, Y. Huang, M. Cui, R.L. de Vries, J. Kim, J. May,
M.A. Tocilescu, W. Liu, H.S. Ko, J. Magrane, D.J. Moore, V.L. Dawson, R. Grailhe,
T.M. Dawson, C. Li, K. Tieu, S. Przedborski, PINK1-dependent recruitment of
Parkin to mitochondria in mitophagy, Proc. Natl. Acad. Sci. USA 107 (2010)
378–383.
[30] R.J. Youle, D.P. Narendra, Mechanisms of mitophagy, Nat. Rev. Mol. Cell Biol. 12
(2011) 9–14.
[31] D.R. Green, L. Galluzzi, G. Kroemer, Cell biology. Metabolic control of cell death,
Science 345 (2014) 1250256.
[32] N.R. Madamanchi, M.S. Runge, Mitochondrial dysfunction in atherosclerosis, Circ.
Res. 100 (2007) 460–473.
[33] S. Mai, M. Klinkenberg, G. Auburger, J. Bereiter-Hahn, M. Jendrach, Decreased
expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells
and enhances resistance to oxidative stress through PINK1, J. Cell Sci. 123 (2010)
917–926.
[34] A.N. Higdon, G.A. Benavides, B.K. Chacko, X. Ouyang, M.S. Johnson, A. Landar,
J. Zhang, V.M. Darley-Usmar, Hemin causes mitochondrial dysfunction in
endothelial cells through promoting lipid peroxidation: the protective role of
autophagy, Am. J. Physiol. Heart Circ. Physiol. 302 (2012) H1394–H1409.
[35] Q. Wang, B. Liang, N.A. Shirwany, M.H. Zou, 2-Deoxy-D-glucose treatment of
endothelial cells induces autophagy by reactive oxygen species-mediated activa-
tion of the AMP-activated protein kinase, PLoS One 6 (2011) e17234.
[36] W. Wu, H. Xu, Z. Wang, Y. Mao, L. Yuan, W. Luo, Z. Cui, T. Cui, X.L. Wang,
Y.H. Shen, PINK1-Parkin-Mediated Mitophagy Protects Mitochondrial Integrity
and Prevents Metabolic Stress-Induced Endothelial Injury, PLoS One 10 (2015)
e0132499.
[37] F. Madeo, N. Tavernarakis, G. Kroemer, Can autophagy promote longevity? Nat.
Cell Biol. 12 (2010) 842–846.
[38] G. Helmlinger, M. Endo, N. Ferrara, L. Hlatky, R.K. Jain, Formation of endothelial
cell networks, Nature 405 (2000) 139–141.
[39] A.G. Tsai, B. Friesenecker, M.C. Mazzoni, H. Kerger, D.G. Buerk, P.C. Johnson,
M. Intaglietta, Microvascular and tissue oxygen gradients in the rat mesentery,
Proc. Natl. Acad. Sci. USA 95 (1998) 6590–6595.
[40] A.G. Tsai, P.C. Johnson, M. Intaglietta, Oxygen gradients in the microcirculation,
Physiol. Rev. 83 (2003) 933–963.
[41] A.S. Golub, B.K. Song, R.N. Pittman, The rate of O(2) loss from mesenteric
arterioles is not unusually high, Am. J. Physiol. Heart Circ. Physiol. 301 (2011)
H737–H745.
[42] B.P. Dranka, B.G. Hill, V.M. Darley-Usmar, Mitochondrial reserve capacity in
endothelial cells: the impact of nitric oxide and reactive oxygen species, Free
Radic. Biol. Med. 48 (2010) 905–914.
[43] S. Mertens, T. Noll, R. Spahr, A. Krutzfeldt, H.M. Piper, Energetic response of
coronary endothelial cells to hypoxia, Am. J. Physiol. 258 (1990) H689–H694.
[44] G.L. Wright, I.G. Maroulakou, J. Eldridge, T.L. Liby, V. Sridharan, P.N. Tsichlis,
R.C. Muise-Helmericks, VEGF stimulation of mitochondrial biogenesis: require-
ment of AKT3 kinase, FASEB J. 22 (2008) 3264–3275.
[45] A. Csiszar, N. Labinskyy, J.T. Pinto, P. Ballabh, H. Zhang, G. Losonczy, K. Pearson,
R. de Cabo, P. Pacher, C. Zhang, Z. Ungvari, Resveratrol induces mitochondrial
biogenesis in endothelial cells, Am. J. Physiol. Heart Circ. Physiol. 297 (2009)
H13–H20.
[46] M. Haslip, I. Dostanic, Y. Huang, Y. Zhang, K.S. Russell, M.J. Jurczak, P. Mannam,
F. Giordano, S.C. Erzurum, P.J. Lee, Endothelial uncoupling protein 2 regulates
mitophagy and pulmonary hypertension during intermittent hypoxia, Arterioscler.
Thromb. Vasc. Biol. 35 (2015) 1166–1178.
[47] M.T. Neary, K.E. Ng, M.H. Ludtmann, A.R. Hall, I. Piotrowska, S.B. Ong,
D.J. Hausenloy, T.J. Mohun, A.Y. Abramov, R.A. Breckenridge, Hypoxia signaling
controls postnatal changes in cardiac mitochondrial morphology and function, J.
Mol. Cell. Cardiol. 74 (2014) 340–352.
[48] K. Wilhelm, K. Happel, G. Eelen, S. Schoors, M.F. Oellerich, R. Lim,
B. Zimmermann, I.M. Aspalter, C.A. Franco, T. Boettger, T. Braun, M. Fruttiger,
K. Rajewsky, C. Keller, J.C. Bruning, H. Gerhardt, P. Carmeliet, M. Potente, FOXO1
couples metabolic activity and growth state in the vascular endothelium, Nature
529 (2016) 216–220.
[49] K. De Bock, M. Georgiadou, S. Schoors, A. Kuchnio, B.W. Wong, A.R. Cantelmo,
A. Quaegebeur, B. Ghesquiere, S. Cauwenberghs, G. Eelen, L.K. Phng, I. Betz,
B. Tembuyser, K. Brepoels, J. Welti, I. Geudens, I. Segura, B. Cruys, F. Bifari,
I. Decimo, R. Blanco, S. Wyns, J. Vangindertael, S. Rocha, R.T. Collins, S. Munck,
D. Daelemans, H. Imamura, R. Devlieger, M. Rider, P.P. Van Veldhoven, F. Schuit,
R. Bartrons, J. Hofkens, P. Fraisl, S. Telang, R.J. Deberardinis, L. Schoonjans,
S. Vinckier, J. Chesney, H. Gerhardt, M. Dewerchin, P. Carmeliet, Role of PFKFB3-
driven glycolysis in vessel sprouting, Cell 154 (2013) 651–663.
[50] S. Schoors, U. Bruning, R. Missiaen, K.C. Queiroz, G. Borgers, I. Elia, A. Zecchin,
A.R. Cantelmo, S. Christen, J. Goveia, W. Heggermont, L. Godde, S. Vinckier,
P.P. Van Veldhoven, G. Eelen, L. Schoonjans, H. Gerhardt, M. Dewerchin, M. Baes,
K. De Bock, B. Ghesquiere, S.Y. Lunt, S.M. Fendt, P. Carmeliet, Fatty acid carbon is
essential for dNTP synthesis in endothelial cells, Nature 520 (2015) 192–197.
[51] C.R. Triggle, S.M. Samuel, S. Ravishankar, I. Marei, G. Arunachalam, H. Ding, The
endothelium: influencing vascular smooth muscle in many ways, Can. J. Physiol.
Pharmacol. 90 (2012) 713–738.
[52] M. Pangare, A. Makino, Mitochondrial function in vascular endothelial cell in
diabetes, J. Smooth Muscle Res. 48 (2012) 1–26.
[53] K. Mishiro, T. Imai, S. Sugitani, A. Kitashoji, Y. Suzuki, T. Takagi, H. Chen,
Y. Oumi, K. Tsuruma, M. Shimazawa, H. Hara, Diabetes mellitus aggravates
hemorrhagic transformation after ischemic stroke via mitochondrial defects
leading to endothelial apoptosis, PLoS One 9 (2014) e103818.
[54] L. Zhu, G. Sun, H. Zhang, Y. Zhang, X. Chen, X. Jiang, X. Jiang, S. Krauss, J. Zhang,
Y. Xiang, C.Y. Zhang, PGC-1alpha is a key regulator of glucose-induced prolif-
eration and migration in vascular smooth muscle cells, PLoS One 4 (2009) e4182.
[55] H. Peng, W. Zhong, H. Zhao, L. Chen, X. Zhou, F. Li, W. Zhu, G. Li, Lack of PGC-
1alpha exacerbates high glucose-induced apoptosis in human umbilical vein
endothelial cells through activation of VADC1, Int. J. Clin. Exp. Pathol. 8 (2015)
4639–4650.
[56] N. Sawada, A. Jiang, F. Takizawa, A. Safdar, A. Manika, Y. Tesmenitsky,
K.T. Kang, J. Bischoff, H. Kalwa, J.L. Sartoretto, Y. Kamei, L.E. Benjamin,
H. Watada, Y. Ogawa, Y. Higashikuni, C.W. Kessinger, F.A. Jaffer, T. Michel,
M. Sata, K. Croce, R. Tanaka, Z. Arany, Endothelial PGC-1alpha mediates vascular
dysfunction in diabetes, Cell Metab. 19 (2014) 246–258.
[57] S.M. Craige, S. Kroller-Schon, C. Li, S. Kant, S. Cai, K. Chen, M.M. Contractor,
Y. Pei, E. Schulz, J.F. Keaney Jr., PGC-1alpha dictates endothelial function through
regulation of eNOS expression, Sci. Rep. 6 (2016) 38210.
[58] Z. Dagher, N. Ruderman, K. Tornheim, Y. Ido, The effect of AMP-activated protein
kinase and its activator AICAR on the metabolism of human umbilical vein
S. Caja, J.A. Enríquez Redox Biology 12 (2017) 821–827
825
endothelial cells, Biochem. Biophys. Res. Commun. 265 (1999) 112–115.
[59] Z. Dagher, N. Ruderman, K. Tornheim, Y. Ido, Acute regulation of fatty acid
oxidation and amp-activated protein kinase in human umbilical vein endothelial
cells, Circ. Res. 88 (2001) 1276–1282.
[60] W.C. Hulsmann, M.L. Dubelaar, Aspects of fatty acid metabolism in vascular
endothelial cells, Biochimie 70 (1988) 681–686.
[61] W.C. Hulsmann, M.L. Dubelaar, Carnitine requirement of vascular endothelial and
smooth muscle cells in imminent ischemia, Mol. Cell. Biochem. 116 (1992)
125–129.
[62] L. Fang, S.H. Choi, J.S. Baek, C. Liu, F. Almazan, F. Ulrich, P. Wiesner, A. Taleb,
E. Deer, J. Pattison, J. Torres-Vazquez, A.C. Li, Y.I. Miller, Control of angiogenesis
by AIBP-mediated cholesterol efflux, Nature 498 (2013) 118–122.
[63] K.F. Teunissen-Beekman, J. Dopheide, J.M. Geleijnse, S.J. Bakker, E.J. Brink,
P.W. de Leeuw, C.G. Schalkwijk, M.A. van Baak, Dietary proteins improve
endothelial function under fasting conditions but not in the postprandial state,
with no effects on markers of low-grade inflammation, Br. J. Nutr. 114 (2015)
1819–1828.
[64] C.V. Dang, Links between metabolism and cancer, Genes Dev. 26 (2012) 877–890.
[65] R.J. DeBerardinis, C.B. Thompson, Cellular metabolism and disease: what do
metabolic outliers teach us? Cell 148 (2012) 1132–1144.
[66] S.C. Kalhan, R.W. Hanson, Resurgence of serine: an often neglected but indis-
pensable amino Acid, J. Biol. Chem. 287 (2012) 19786–19791.
[67] J.M. Phang, W. Liu, Proline metabolism and cancer, Front. Biosci. (Landmark Ed.)
17 (2012) 1835–1845.
[68] N. Shyh-Chang, J.W. Locasale, C.A. Lyssiotis, Y. Zheng, R.Y. Teo,
S. Ratanasirintrawoot, J. Zhang, T. Onder, J.J. Unternaehrer, H. Zhu, J.M. Asara,
G.Q. Daley, L.C. Cantley, Influence of threonine metabolism on S-adenosyl-
methionine and histone methylation, Science 339 (2013) 222–226.
[69] R. Lohmann, W.W. Souba, B.P. Bode, Rat liver endothelial cell glutamine
transporter and glutaminase expression contrast with parenchymal cells, Am. J.
Physiol. 276 (1999) G743–G750.
[70] H. Unterluggauer, S. Mazurek, B. Lener, E. Hutter, E. Eigenbrodt, W. Zwerschke,
P. Jansen-Durr, Premature senescence of human endothelial cells induced by
inhibition of glutaminase, Biogerontology 9 (2008) 247–259.
[71] I.S. Park, S.W. Kang, Y.J. Shin, K.Y. Chae, M.O. Park, M.Y. Kim, D.N. Wheatley,
B.H. Min, Arginine deiminase: a potential inhibitor of angiogenesis and tumour
growth, Br. J. Cancer 89 (2003) 907–914.
[72] W. Zhuo, X. Song, H. Zhou, Y. Luo, Arginine deiminase modulates endothelial tip
cells via excessive synthesis of reactive oxygen species, Biochem. Soc. Trans. 39
(2011) 1376–1381 (suppl 1372 p following 1382).
[73] Y.S. Chatzizisis, A.U. Coskun, M. Jonas, E.R. Edelman, C.L. Feldman, P.H. Stone,
Role of endothelial shear stress in the natural history of coronary atherosclerosis
and vascular remodeling: molecular, cellular, and vascular behavior, J. Am. Coll.
Cardiol. 49 (2007) 2379–2393.
[74] H.J. Hsieh, C.A. Liu, B. Huang, A.H. Tseng, D.L. Wang, Shear-induced endothelial
mechanotransduction: the interplay between reactive oxygen species (ROS) and
nitric oxide (NO) and the pathophysiological implications, J. Biomed. Sci. 21
(2014) 3.
[75] J.P. Huddleson, N. Ahmad, S. Srinivasan, J.B. Lingrel, Induction of KLF2 by fluid
shear stress requires a novel promoter element activated by a phosphatidylinositol
3-kinase-dependent chromatin-remodeling pathway, J. Biol. Chem. 280 (2005)
23371–23379.
[76] Z.G. Jin, H. Ueba, T. Tanimoto, A.O. Lungu, M.D. Frame, B.C. Berk, Ligand-
independent activation of vascular endothelial growth factor receptor 2 by fluid
shear stress regulates activation of endothelial nitric oxide synthase, Circ. Res. 93
(2003) 354–363.
[77] M.J. Kuchan, J.A. Frangos, Role of calcium and calmodulin in flow-induced nitric
oxide production in endothelial cells, Am. J. Physiol. 266 (1994) C628–C636.
[78] P. Silacci, K. Formentin, K. Bouzourene, F. Daniel, H.R. Brunner, D. Hayoz,
Unidirectional and oscillatory shear stress differentially modulate NOS III gene
expression, Nitric Oxide 4 (2000) 47–56.
[79] L. Ai, M. Rouhanizadeh, J.C. Wu, W. Takabe, H. Yu, M. Alavi, R. Li, Y. Chu,
J. Miller, D.D. Heistad, T.K. Hsiai, Shear stress influences spatial variations in
vascular Mn-SOD expression: implication for LDL nitration, Am. J. Physiol. Cell.
Physiol. 294 (2008) C1576–C1585.
[80] G.P. Sorescu, H. Song, S.L. Tressel, J. Hwang, S. Dikalov, D.A. Smith, N.L. Boyd,
M.O. Platt, B. Lassegue, K.K. Griendling, H. Jo, Bone morphogenic protein 4
produced in endothelial cells by oscillatory shear stress induces monocyte
adhesion by stimulating reactive oxygen species production from a nox1-based
NADPH oxidase, Circ. Res. 95 (2004) 773–779.
[81] C.G. Scheitlin, D.M. Nair, J.A. Crestanello, J.L. Zweier, B.R. Alevriadou, Fluid
Mechanical Forces and Endothelial Mitochondria: a Bioengineering Perspective,
Cell. Mol. Bioeng. 7 (2014) 483–496.
[82] Z. Han, Y.R. Chen, C.I. Jones 3rd, G. Meenakshisundaram, J.L. Zweier,
B.R. Alevriadou, Shear-induced reactive nitrogen species inhibit mitochondrial
respiratory complex activities in cultured vascular endothelial cells, Am. J.
Physiol. Cell. Physiol. 292 (2007) C1103–C1112.
[83] R. Breton-Romero, R. Acin-Perez, F. Rodriguez-Pascual, M. Martinez-Molledo,
R.P. Brandes, E. Rial, J.A. Enriquez, S. Lamas, Laminar shear stress regulates
mitochondrial dynamics, bioenergetics responses and PRX3 activation in en-
dothelial cells, Biochim. Biophys. Acta 1843 (2014) 2403–2413.
[84] F. Guo, X. Li, J. Peng, Y. Tang, Q. Yang, L. Liu, Z. Wang, Z. Jiang, M. Xiao, C. Ni,
R. Chen, D. Wei, G.X. Wang, Autophagy regulates vascular endothelial cell eNOS
and ET-1 expression induced by laminar shear stress in an ex vivo perfused system,
Ann. Biomed. Eng. 42 (2014) 1978–1988.
[85] W. Takabe, N. Jen, L. Ai, R. Hamilton, S. Wang, K. Holmes, F. Dharbandi,
B. Khalsa, S. Bressler, M.L. Barr, R. Li, T.K. Hsiai, Oscillatory shear stress induces
mitochondrial superoxide production: implication of NADPH oxidase and c-Jun
NH2-terminal kinase signaling, Antioxid. Redox Signal. 15 (2011) 1379–1388.
[86] A. Young, W. Wu, W. Sun, H. Benjamin Larman, N. Wang, Y.S. Li, J.Y. Shyy,
S. Chien, G. Garcia-Cardena, Flow activation of AMP-activated protein kinase in
vascular endothelium leads to Kruppel-like factor 2 expression, Arterioscler.
Thromb. Vasc. Biol. 29 (2009) 1902–1908.
[87] M.P. Murphy, How mitochondria produce reactive oxygen species, Biochem. J.
417 (2009) 1–13.
[88] F. Chen, S. Haigh, S. Barman, D.J. Fulton, From form to function: the role of Nox4
in the cardiovascular system, Front. Physiol. 3 (2012) 412.
[89] M. Santillo, A. Colantuoni, P. Mondola, B. Guida, S. Damiano, NOX signaling in
molecular cardiovascular mechanisms involved in the blood pressure homeostasis,
Front. Physiol. 6 (2015) 194.
[90] T.B. Li, J.J. Zhang, B. Liu, W.Q. Liu, Y. Wu, X.M. Xiong, X.J. Luo, Q.L. Ma, J. Peng,
Involvement of NADPH oxidases and non-muscle myosin light chain in senescence
of endothelial progenitor cells in hyperlipidemia, Naunyn Schmiede. Arch.
Pharmacol. (2015).
[91] A.M. Amanso, K.K. Griendling, Differential roles of NADPH oxidases in vascular
physiology and pathophysiology, Front. Biosci. (Schol Ed), 4 (2012) pp.
1044–1064.
[92] P.W. Kleikers, V.T. Dao, E. Gob, C. Hooijmans, J. Debets, H. van Essen,
C. Kleinschnitz, H.H. Schmidt, SFRR-E Young Investigator AwardeeNOXing out
stroke: identification of NOX4 and 5as targets in blood-brain-barrier stabilisation
and neuroprotection, Free Radic. Biol. Med. 75 (Suppl 1) (2014) S16.
[93] F. Paneni, F. Cosentino, p66 Shc as the engine of vascular aging, Curr. Vasc.
Pharmacol. 10 (2012) 697–699.
[94] F. Paneni, P. Mocharla, A. Akhmedov, S. Costantino, E. Osto, M. Volpe,
T.F. Luscher, F. Cosentino, Gene silencing of the mitochondrial adaptor p66(Shc)
suppresses vascular hyperglycemic memory in diabetes, Circ. Res. 111 (2012)
278–289.
[95] A.Y. Andreyev, Y.E. Kushnareva, A.N. Murphy, A.A. Starkov, Mitochondrial ROS
metabolism: 10 years later, Biochemistry (Mosc.) 80 (2015) 517–531.
[96] G.G. Camici, M. Schiavoni, P. Francia, M. Bachschmid, I. Martin-Padura,
M. Hersberger, F.C. Tanner, P. Pelicci, M. Volpe, P. Anversa, T.F. Luscher,
F. Cosentino, Genetic deletion of p66(Shc) adaptor protein prevents hyperglyce-
mia-induced endothelial dysfunction and oxidative stress, Proc. Natl. Acad. Sci.
USA 104 (2007) 5217–5222.
[97] M. Giorgio, E. Migliaccio, F. Orsini, D. Paolucci, M. Moroni, C. Contursi,
G. Pelliccia, L. Luzi, S. Minucci, M. Marcaccio, P. Pinton, R. Rizzuto, P. Bernardi,
F. Paolucci, P.G. Pelicci, Electron transfer between cytochrome c and p66Shc
generates reactive oxygen species that trigger mitochondrial apoptosis, Cell 122
(2005) 221–233.
[98] M. Trinei, I. Berniakovich, E. Beltrami, E. Migliaccio, A. Fassina, P. Pelicci,
M. Giorgio, P66Shc signals to age, Aging (Albany NY) 1 (2009) 503–510.
[99] S. Meresse, M.P. Dehouck, P. Delorme, M. Bensaid, J.P. Tauber, C. Delbart,
J.C. Fruchart, R. Cecchelli, Bovine brain endothelial cells express tight junctions
and monoamine oxidase activity in long-term culture, J. Neurochem. 53 (1989)
1363–1371.
[100] N. Kaludercic, E. Takimoto, T. Nagayama, N. Feng, E.W. Lai, D. Bedja, K. Chen,
K.L. Gabrielson, R.D. Blakely, J.C. Shih, K. Pacak, D.A. Kass, F. Di Lisa, N. Paolocci,
Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contri-
butes to adverse remodeling and pump failure in hearts with pressure overload,
Circ. Res. 106 (2010) 193–202.
[101] C.C. Poon, S.W. Seto, A.L. Au, Q. Zhang, R.W. Li, W.Y. Lee, G.P. Leung, S.K. Kong,
J.H. Yeung, S.M. Ngai, H.P. Ho, S.M. Lee, S.W. Chan, Y.W. Kwan, Mitochondrial
monoamine oxidase-A-mediated hydrogen peroxide generation enhances 5-hy-
droxytryptamine-induced contraction of rat basilar artery, Br. J. Pharmacol. 161
(2010) 1086–1098.
[102] D.B. Zorov, M. Juhaszova, S.J. Sollott, Mitochondrial reactive oxygen species
(ROS) and ROS-induced ROS release, Physiol. Rev. 94 (2014) 909–950.
[103] A. Daiber, Redox signaling (cross-talk) from and to mitochondria involves
mitochondrial pores and reactive oxygen species, Biochim. Biophys. Acta 1797
(2010) 897–906.
[104] A.K. Doughan, D.G. Harrison, S.I. Dikalov, Molecular mechanisms of angiotensin
II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage
and vascular endothelial dysfunction, Circ. Res. 102 (2008) 488–496.
[105] R.S. Richardson, A.J. Donato, A. Uberoi, D.W. Wray, L. Lawrenson, S. Nishiyama,
D.M. Bailey, Exercise-induced brachial artery vasodilation: role of free radicals,
Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1516–H1522.
[106] R. Stocker, J.F. Keaney Jr., Role of oxidative modifications in atherosclerosis,
Physiol. Rev. 84 (2004) 1381–1478.
[107] E.K. Ceaser, A. Ramachandran, A.L. Levonen, V.M. Darley-Usmar, Oxidized low-
density lipoprotein and 15-deoxy-delta 12,14-PGJ2 increase mitochondrial com-
plex I activity in endothelial cells, Am. J. Physiol. Heart Circ. Physiol. 285 (2003)
H2298–H2308.
[108] L. Mabile, O. Meilhac, I. Escargueil-Blanc, M. Troly, M.T. Pieraggi, R. Salvayre,
A. Negre-Salvayre, Mitochondrial function is involved in LDL oxidation mediated
by human cultured endothelial cells, Arterioscler. Thromb. Vasc. Biol. 17 (1997)
1575–1582.
[109] R. Zhao, G.X. Shen, Functional modulation of antioxidant enzymes in vascular
endothelial cells by glycated LDL, Atherosclerosis 179 (2005) 277–284.
[110] D.G. Harrison, M.C. Gongora, Oxidative stress and hypertension, Med. Clin. North
Am. 93 (2009) 621–635.
[111] J.B. Laursen, S. Rajagopalan, Z. Galis, M. Tarpey, B.A. Freeman, D.G. Harrison,
Role of superoxide in angiotensin II-induced but not catecholamine-induced
S. Caja, J.A. Enríquez Redox Biology 12 (2017) 821–827
826
hypertension, Circulation 95 (1997) 588–593.
[112] K. Miyagawa, M. Ohashi, S. Yamashita, M. Kojima, K. Sato, R. Ueda, Y. Dohi,
Increased oxidative stress impairs endothelial modulation of contractions in
arteries from spontaneously hypertensive rats, J. Hypertens. 25 (2007) 415–421.
[113] K. Nakazono, N. Watanabe, K. Matsuno, J. Sasaki, T. Sato, M. Inoue, Does
superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA
88 (1991) 10045–10048.
[114] C.G. Schnackenberg, W.J. Welch, C.S. Wilcox, Normalization of blood pressure
and renal vascular resistance in SHR with a membrane-permeable superoxide
dismutase mimetic: role of nitric oxide, Hypertension 32 (1998) 59–64.
[115] N.E. Hoch, T.J. Guzik, W. Chen, T. Deans, S.A. Maalouf, P. Gratze, C. Weyand,
D.G. Harrison, Regulation of T-cell function by endogenously produced angio-
tensin II, Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009) R208–R216.
[116] M.E. Pueyo, W. Gonzalez, A. Nicoletti, F. Savoie, J.F. Arnal, J.B. Michel,
Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear
factor-kappaB activation induced by intracellular oxidative stress, Arterioscler.
Thromb. Vasc. Biol. 20 (2000) 645–651.
[117] J.D. Widder, D. Fraccarollo, P. Galuppo, J.M. Hansen, D.P. Jones, G. Ertl,
J. Bauersachs, Attenuation of angiotensin II-induced vascular dysfunction and
hypertension by overexpression of Thioredoxin 2, Hypertension 54 (2009)
338–344.
[118] D. Graham, N.N. Huynh, C.A. Hamilton, E. Beattie, R.A. Smith, H.M. Cocheme,
M.P. Murphy, A.F. Dominiczak, Mitochondria-targeted antioxidant MitoQ10
improves endothelial function and attenuates cardiac hypertrophy, Hypertension
54 (2009) 322–328.
[119] G. Basta, G. Lazzerini, S. Del Turco, G.M. Ratto, A.M. Schmidt, R. De Caterina, At
least 2 distinct pathways generating reactive oxygen species mediate vascular cell
adhesion molecule-1 induction by advanced glycation end products, Arterioscler.
Thromb. Vasc. Biol. 25 (2005) 1401–1407.
[120] S. Srinivasan, M. Yeh, E.C. Danziger, M.E. Hatley, A.E. Riggan, N. Leitinger,
J.A. Berliner, C.C. Hedrick, Glucose regulates monocyte adhesion through
endothelial production of interleukin-8, Circ. Res. 92 (2003) 371–377.
[121] T. Yu, J.L. Robotham, Y. Yoon, Increased production of reactive oxygen species in
hyperglycemic conditions requires dynamic change of mitochondrial morphology,
Proc. Natl. Acad. Sci. USA 103 (2006) 2653–2658.
[122] M. Brownlee, Biochemistry and molecular cell biology of diabetic complications,
Nature 414 (2001) 813–820.
[123] L.G. Nijtmans, N.S. Henderson, G. Attardi, I.J. Holt, Impaired ATP synthase
assembly associated with a mutation in the human ATP synthase subunit 6 gene, J.
Biol. Chem. 276 (2001) 6755–6762.
S. Caja, J.A. Enríquez Redox Biology 12 (2017) 821–827
827
